Home
>
National Drug Code (NDC)
>
Griseofulvin
Griseofulvin - 0093-7102-12 - (Griseofulvin)
Drug Information of Griseofulvin
| Product NDC: | 0093-7102 |
| Proprietary Name: | Griseofulvin |
| Non Proprietary Name: | Griseofulvin |
| Active Ingredient(s): | 125 mg/5mL & nbsp; Griseofulvin |
| Administration Route(s): | ORAL |
| Dosage Form(s): | SUSPENSION |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of Griseofulvin
| Product NDC: | 0093-7102 |
| Labeler Name: | TevaPharmaceuticals USA Inc |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | ANDA065354 |
| Marketing Category: | ANDA |
| Start Marketing Date: | 20080212 |
Package Information of Griseofulvin
| Package NDC: | 0093-7102-12 |
| Package Description: | 120 mL in 1 BOTTLE (0093-7102-12) |
NDC Information of Griseofulvin
| NDC Code | 0093-7102-12 |
| Proprietary Name | Griseofulvin |
| Package Description | 120 mL in 1 BOTTLE (0093-7102-12) |
| Product NDC | 0093-7102 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | Griseofulvin |
| Dosage Form Name | SUSPENSION |
| Route Name | ORAL |
| Start Marketing Date | 20080212 |
| Marketing Category Name | ANDA |
| Labeler Name | TevaPharmaceuticals USA Inc |
| Substance Name | GRISEOFULVIN |
| Strength Number | 125 |
| Strength Unit | mg/5mL |
| Pharmaceutical Classes | Decreased Mitosis [PE],Microtubule Inhibition [PE],Tubulin Inhibiting Agent [EPC] |
